Person: ERMERAK, NEZİH ONUR
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ERMERAK
First Name
NEZİH ONUR
Name
55 results
Search Results
Now showing 1 - 10 of 55
Publication Metadata only Epithelioid malignant pleural mesothelioma: Importance of extrapleural lymph node metastasis and trimodality treatment(2015-05-31) ERMERAK, NEZİH ONUR; LAÇİN, TUNÇ; AHISKALI, ASİYE RENGİN; YILDIZELİ, BEDRETTİN; BATIREL H. F., ERMERAK N. O., LAÇİN T., METİNTAŞ M., AK G., YUMUK P. F., ÖZKÖK H. B., AHISKALI A. R., YILDIZELİ B., YÜKSEL M.Publication Metadata only Kist hidatik'i taklit eden silyalı mukodüller papiller tümör(2023-10-19) ERMERAK, NEZİH ONUR; YILDIZELİ, BEDRETTİN; Ertan R., ASLAN S., ERMERAK N. O., YILDIZELİ B.Publication Metadata only Pektus karinatumun minimal invaziv yöntemle tedavisi(2018-05-01) ERMERAK, NEZİH ONUR; YÜKSEL M., ERMERAK N. O.Pektus Karinatum (PK) ikinci en sık görülen konjenital göğüs duvarı deformitesidir. Ergenlikle birlikte deformite belirginleşerek kozmetik ve psikososyal sorunlara yol açmaktadır. Günümüzde Pektus Karinatum'un cerrahi tedavisinden Minimal Invaziv Yöntemle Pektus Karinatum Onarımı (MIRPC) tercih edilen tedavi metodu halini almıştır. Bu bölümde; operasyonun preoperatif ve postoperatif süreci ile birlikte cerrahi teknik ile ilgili bilgiler aktarılması amaçlanmıştır.Publication Metadata only Preoperative Chemoradiation Therapy Decreases the Number of Lymph Nodes Resected During Esophagectomy(SPRINGER, 2015) ÇELİKEL, ÇİĞDEM; Issaka, Adamu; Ermerak, Nezih Onur; Bilgi, Zeynep; Kara, Volkan Hasan; Celikel, Cigdem Ataizi; Batirel, Hasan FevziBackground This study aimed to analyze the effect of preoperative chemoradiation on the adequacy of lymph node dissection. Methods Patients with esophageal cancer treated with esophagectomy by the same surgeon between 2004 and 2011 were reviewed. Specimens were examined by the same pathologist. Patients were grouped into two depending on the type of treatment received. Results Forty-seven patients with curative esophagectomy were included in the study. Twenty patients had preoperative chemoradiation followed by surgery and 27 had surgery alone. Open and hybrid esophagectomy approaches were used. The average number of lymph nodes dissected was 16 +/- 10 (1-39). There was a significant decrease in the number of lymph nodes examined in patients with preoperative chemoradiotherapy in comparison to surgery alone (p = 0.001). Median length of stay was 12 days. R0 resection rate was 96 %. The median survival was 36.3 months, with a 42 % 5-year survival. Seven patients (25 %) had complete pathologic response following chemoradiation. No significant difference was recorded in terms of disease recurrence (p = 0.3). While morbidity was higher in the preoperative therapy group with 30 day mortality of 10 %, type of surgical approach does not seem to influence the number of lymph nodes dissected (p = 0.7). Conclusions Preoperative chemoradiation decreases the number of harvested lymph nodes following esophagectomy regardless of the surgical technique used. The optimum number of lymph nodes currently recommended to be dissected for accurate nodal staging and survival needs revision in this group of patients.Publication Metadata only Reconstruction of sternal cleft with autologous cartilage graft in an adult(2015-06-01) ERMERAK, NEZİH ONUR; BOSTANCI, KORKUT; YÜKSEL, MUSTAFA; KURU P., ERMERAK N. O., BOSTANCI K., YÜKSEL M.Sternal cleft is a rare chest wall deformity associated with various malformations. Primary closure is the gold standard in the newborn period. Alternative techniques are possible for older patients. A 23-year-old woman with a partial sternal cleft and no additional deformity, underwent reconstruction using costal cartilage grafts. Postoperative physical and functional were excellent.Publication Metadata only Histopathological evaluation of post-mortem pulmonary specimens excised from ICU patients with COVID-19: Do we know what we do not know(2023-05-06) ERMERAK, NEZİH ONUR; BOZKURTLAR, EMİNE; KOCAKAYA, DERYA; GÜL, FETHİ; KARAKURT, SAİT; ERMERAK N. O., BOZKURTLAR E., KOCAKAYA D., GÜL F., KARAKURT S., Cinel I.Publication Open Access Esophageal perforation during intragastric balloon therapy: management of a patient with late referral(2023-01-01) ERMERAK, NEZİH ONUR; UPRAK, TEVFİK KIVILCIM; LAÇİN, TUNÇ; YILDIZELİ, BEDRETTİN; YEGEN, ŞEVKET CUMHUR; ERMERAK N. O., Uprak K. T., Emran M., LAÇİN T., YILDIZELİ B., YEGEN Ş. C.Minimally invasive treatment modalities like intragastric balloon therapy (IBT) gained popularity in the treatment of obesity [1]. Some morbidities have been reported in the literature, but it is limited. Esophageal perforation is the most feared complication of the procedure. Although endoscopic stent placement can be chosen as a treatment option in stable patients, most of the patients are treated with surgical drainage and primary repair [2]. We report an unusual case of intragastric balloon placement complicated with esophageal perforation which was successfully treated with a surgical approach after late referral.Publication Metadata only Treatment of pectus excavatum(Akademisyen Yayınevi, 2021-01-01) ERMERAK, NEZİH ONUR; YÜKSEL M., ERMERAK N. O.Publication Metadata only 18 years of experience in Minimally Invasive Pectus Surgery: Bar Removal(2022-09-14) ERMERAK, NEZİH ONUR; LAÇİN, TUNÇ; ERMERAK N. O., ASLAN S., YAMANSAVCI ŞİRZAİ E., LAÇİN T., YÜKSEL M.Publication Open Access Clinical validation of an activity-based enzyme assay for early stage lung cancer(2023-06-02) ERMERAK, NEZİH ONUR; Dempsey P., Sandu Aparacio C., Gonzalezirias R., Hantula S., Kagawa M., Bossmann S. H., Covarrubias-Zambrano O., Nagji A. S., Veeramachaneni N. K., ERMERAK N. O., et al.Background: The USPSTF guidelines recommend annual LDCT scans for 15.5 million adults with a heavy smoking history. While LDCT can reduce deaths by 20%, screening compliance remains low. A blood test with clinically useful, cost effective performance could improve compliance and access when integrated with the standard of care. We describe here a lyophilized nanosensor system for detecting protease enzyme activity in sera with clinically useful diagnostic activity in early stage lung cancer. We evaluated the performance of the assay by examination of prospectively collected sera for detection of cancer in high risk patients. Methods: Sera were obtained in multiple independent studies to include pathologically confirmed, treatment naive lung cancer patients and LDCT confirmed negative individuals. Protease activity was measured on 18 different nanosensors built with protease targets mainly selective for members of the Matrix Metalloproteinase and Cathepsin families. Lyophilized plates were incubated with serum and enzyme activity was measured indirectly as a continuous variable by a fluorescent plate reader. A machine learning modeling tool (Emerge) was used to detect signal associated with a cancer “fingerprint” of protease activity. The analysis stratified allocation into training and testing sets of 250 samples each and reserved a third out of sample validation set (250 samples) for reporting. Results: 750 clinical samples included 30% lung cancers, 63% males, 91% smokers, and an average age of 63 years (SD=9). Cancer cases were distributed across stages I (41%), II (17%), III (20%) and IV (20%) with 5% unknown. Histological classification included 59% adenocarcinoma, 31% squamous cell and 11% other subtypes. Using an Emerge model with only nanosensor activity and gender as inputs, we evolved a balanced algorithm. The algorithm can be further modified to favor sensitivity or specificity depending on the application by applying model weighting factors. We report the performance observed in the 250 out of sample validation set at three points on this spectrum (Table). Among Stage I cancer samples, the balanced algorithm had an accuracy of 90% (26/29). Conclusions: Current LDCT tools show low compliance. We demonstrate clinical validity of a cost effective tool to detect lung cancer in support of LDCT screening. Based on a simple blood sample, the current test may predict early stage lung cancer with an accuracy of 90%. The performance suggests applications in LDCT compliance, post LDCT management, and eventually screening. A clinically validated version of this technology is being evaluated as a triage tool for LDCT screening.